Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat
Ryuzo Bessho and David J. Chambers


The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jtcs.ctsnetjournals.org/cgi/content/full/124/2/340
Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat

Ryuzo Bessho, MD, PhD
David J. Chambers, PhD

Objective: We previously showed that arrest with multidose infusions of high-dose (1 mmol/L) esmolol (an ultra-short-acting β-blocker) in oxygenated Krebs-Henseleit buffer (esmolol cardioplegia) provided complete myocardial protection after 40 minutes of normothermic (37°C) global ischemia in isolated rat hearts. In this study we investigated the importance of oxygenation for protection with esmolol cardioplegia, compared it with that of St Thomas’ Hospital cardioplegia, and determined the protective efficacy of multidose esmolol cardioplegia for extended ischemic durations.

Methods: Isolated rat hearts (n = 6/group) were perfused in the Langendorff mode at constant pressure (75 mm Hg) with oxygenated Krebs-Henseleit bicarbonate buffer at 37°C. The first part of the first study had four groups: (i) multidose (every 15 minutes) oxygenated (95% oxygen/5% carbon dioxide) Krebs-Henseleit buffer during 60 minutes of global ischemia, (ii) multidose deoxygenated (95% nitrogen/5% carbon dioxide) Krebs-Henseleit buffer during 60 minutes of global ischemia, (iii) multidose oxygenated esmolol cardioplegia during 60 minutes of global ischemia, and (iv) multidose deoxygenated esmolol cardioplegia during 60 minutes of global ischemia. The second part of the first study had three groups: (v) multidose St Thomas’ Hospital solution during 60 minutes of global ischemia, (vi) multidose oxygenated St Thomas’ Hospital solution during 60 minutes of global ischemia, and (vii) multidose oxygenated esmolol cardioplegia during 60 minutes of global ischemia. Infusion of esmolol cardioplegia at constant pressure provided complete protection for 60, 75, and 90 minutes (104% ± 5%, 95% ± 5%, and 95% ± 3%, respectively), whereas protection with constant-flow esmolol cardioplegic infusion was significantly decreased at ischemic durations longer than 60 minutes. This decrease in efficacy of constant-flow esmolol cardio-

From the Cardiac Surgical Research/Cardiothoracic Surgery, The Rayne Institute, Guy’s and St Thomas’ NHS Trust, St Thomas’ Hospital, London, United Kingdom.

Received for publication June 5, 2001; revisions requested Sept 19, 2001; revisions received Nov 13, 2001; accepted for publication Nov 20, 2001.

Address for reprints: David J. Chambers, PhD, Cardiac Surgical Research/Cardiothoracic Surgery, The Rayne Institute, Guy’s and St Thomas’ NHS Trust, St Thomas’ Hospital, London SE1 7EH, United Kingdom (E-mail: david.chambers@kcl.ac.uk).

Copyright © 2002 by The American Association for Thoracic Surgery
0022-5223/2002 $35.00 +0 12/1/121976
Numerous experimental and clinical studies have demonstrated that β-adrenergic antagonists (β-blockers) can attenuate the extent of myocardial injury during ischemia and reperfusion, although the mechanism of the cardioprotective efficacy of these drugs during myocardial ischemia is not completely understood. Possible mechanisms include decreasing heart rate and contractility (with a reduction of myocardial oxygen consumption), decreasing sympathetic tone, altering myocardial substrate use, stabilizing cell membranes, and reducing lipid peroxidation of membrane phospholipids. The utility of β-blockers, however, is limited by their negative inotropic and chronotropic properties, and life-threatening adverse effects related to prolonged β-blockade (eg, shock, bradycardia, bronchospasm, pulmonary edema, and complete heart block) remain a clinical problem. To minimize the risks of adverse effects related to prolonged β-blockade therapy in the critically ill patient, a novel group of ultra–short-acting, titratable β-blockers were designed. Esmolol, the first such intravenous β-blocker, was developed to produce rapid and titratable β-adrenergic blockade with minimal adverse effects. Esmolol is an ultra–short-acting, cardioselective β-blocker that is rapidly hydrolyzed by an esterase in blood cell cytosol to form methanol and an acid metabolite (ASL-8123) that is essentially inactive as a β-blocker. Esmolol has also been shown to protect the heart during cardiac surgery; Sweeney and Frazier were the first to use esmolol in patients with compromised left ventricular function. High doses of esmolol were intravenously infused during continuous perfusion of the coronary arteries with normothermic blood to suppress cardiac inotropy and chronotropy, such that the heart rate was slowed sufficiently (without inducing cardiac arrest) to perform the operation. Since then, experimental and clinical studies have shown that the induction by high-dose esmolol of adequate cardiac surgical conditions has provided myocardial preservation equivalent to or better than cold crystalloid or blood cardioplegia. With this technique, however, which consists of continuous coronary infusion of blood containing esmolol, the surgeon is not provided with a still and blood-free operating field. There have been a few case reports from surgeons noting that high-dose esmolol can arrest the heart when the aorta is calcified and that aortic crossclamping should be avoided.

Previously, we showed that multidose infusion of esmolol cardioplegia in oxygenated buffer completely protected the myocardium during 40 minutes of normothermic (37°C) global ischemia in an isolated rat heart preparation. Moreover, we demonstrated that continuous infusion of esmolol cardioplegia (inducing cardiac arrest) failed to completely protect myocardial function, despite avoidance of ischemia, and was significantly less protective than multidose infusion of esmolol cardioplegia during global ischemia. This study was therefore conducted to investigate the importance of oxygenation in the protective effect of multidose esmolol cardioplegia; in addition, we examined the efficacy of multidose esmolol cardioplegic infusions during prolonged ischemia and sought to determine whether the method of infusion influenced this protection.

Material and Methods

Animals
Adult male Wistar rats (240-300 g body weight; Bantin and Kingman, Hull, UK) were used. All animals received humane care in accordance with the “Guidance on the Operation of the Animals (Scientific Procedures) Act of 1986” published by Her Majesty’s Stationary Office, London, United Kingdom. Rats were anesthetized with 95% oxygen/5% carbon dioxide bubbled through diethyl ether; they were then anticoagulated with intravenously administered heparin (1000 IU/kg body weight).

Heart Isolation and Perfusion
Hearts were rapidly excised from the anesthetized rats and immersed in cold (4°C) Krebs-Henseleit bicarbonate buffer (KHB). The aorta was then cannulated, and the heart was perfused in the Langendorff mode as previously described elsewhere. A unipolar electrocardiogram was obtained through a silver electrode inserted into the free wall of the left ventricle and a reference electrode connected to the aortic cannula; the electrocardiogram was continuously recorded throughout the protocol. All hearts were subjected to an equilibration period of aerobic perfusion for 20 minutes, and baseline readings of left ventricular systolic pressure (in...
millimeters of mercury), left ventricular end-diastolic pressure (LVEDP; in millimeters of mercury), heart rate (in beats per minute), and coronary flow (in milliliters per minute) were then taken. Left ventricular developed pressure (LVDP) was calculated as left ventricular systolic pressure minus LVEDP. Perfusion pressure was monitored continuously through a sidearm of the aortic cannula by means of a second pressure transducer. Coronary flow was measured by timed collection of the coronary effluent. Infusion volume of cardioplegic solution was measured by collecting coronary effluent during infusion of cardioplegic solution.

**Exclusion Criteria**
Hearts not satisfying previously assigned inclusion criteria at the time of the baseline readings (after 20 minutes of aerobic perfusion) were excluded from the study. The acceptable ranges for LVDP, heart rate, and coronary flow were greater than 100 mm Hg, greater than 220 beats/min, and 8 to 16 mL/min, respectively.

**Perfusion Medium**
The perfusion medium was a modified KHB with the following composition: 118.5-mmol/L sodium chloride, 25.0-mmol/L so-

---

Figure 1. For legend see opposite page.
dium hydrogen carbonate, 4.8-mmol/L potassium chloride, 1.2-
mmol/L magnesium sulfate, 1.2-mmol/L potassium dihydrogen
orthophosphate, 1.4-mmol/L calcium chloride, and 11.0-mmol/L
glucose. The buffer was prepared daily and filtered through a 5-μm
pore size cellulose nitrate membrane filter before use. Oxygenated
KHB (oxy-KHB) was continuously gassed with a 95% oxygen/5%
carbon dioxide mixture to yield a pH of 7.4 at 37°C. For deoxy-
genated KHB (deoxy-KHB), the buffer was continuously gassed
with a 95% nitrogen/5% carbon dioxide mixture so that a pH of 7.4
at 37°C was maintained.

Preparation and Administration of Esmolol and St Thomas’ Hospital Cardioplegic Solutions
Esmolol (Brevibloc; Baxter Pharmaceuticals, Crowthorne, Berks-
shire, UK) was provided in vials containing 10 mL of a 250-
mg/mL solution. A 1.0-mmol/L esmolol solution (which we have
previously shown to be the optimal concentration to achieve car-
diac arrest20) was prepared by adding 1.5 mL of the concentrated
esmolol solution to 1000 mL of oxy-KHB. St Thomas’ Hospital
cardioplegic solution No. 2 (STH2) had the following composi-
tion: 110.0-mmol/mL sodium chloride, 16.0-mmol/L magnesium
chloride hexahydrate, 16.0-mmol/L potassium chloride, 1.2-
mmol/L calcium chloride, and 10.0-mmol/mL sodium hydrogen
carbonate. STH2 was prepared daily, adjusted to pH 7.8
when at 37°C, and then filtered through a 5-μm cellulose nitrate
membrane filter before use. These solutions were delivered at
37°C, either at constant pressure of 45 mm Hg or at a constant flow
rate of 14 mL/min for 3 minutes each infusion. Normothermic
(37°C) crystalloid cardioplegia was used in preference to hypo-
thermic crystalloid cardioplegia to avoid the additional protection
associated with hypothermia and thus measure the protective effect
of the cardioplegia itself.

Perfusion Protocol
In all perfusion protocols, each heart was supplied with KHB from
a temperature-regulated reservoir (37°C) at a constant perfusion
pressure equivalent to 75 mm Hg before and after global ischemia.
After equilibration, hearts were subjected to one of three perfusion
protocols, as shown in Figure 1. During the ischemic period, hearts
were immersed in KHB at 37°C (using a temperature-controlled,
water-jacketed heart chamber).

Study 1A: Effects on myocardial protection of oxygenation
during multidose infusion of esmolol cardioplegia. Hearts were
randomly assigned to one of four groups (n = 6 per group): (i)
oxo-KHB, multidose oxy-KHB infused for 3 minutes at 14 mL/
min before and every 15 minutes during 60 minutes of intermit-
tent infusion and global ischemia; (ii) deoxy-KHB, multidose deo-
exy-KHB infused for 3 minutes at 14 mL/min before and every 15
minutes during 60 minutes of intermittent infusion and global
ischemia; (iii) oxyesmolol, multidose oxygenated (95% oxy-
gen/5% carbon dioxide) esmolol infused for 3 minutes at 14
mL/min before and every 15 minutes during 60 minutes of inter-
mittent infusion and global ischemia; and (iv) deoxyesmolol, mul-
dose deoxygenated (95% nitrogen/5% carbon dioxide) esmolol
infused for 3 minutes at 14 mL/min before and every 15 minutes
during 60 minutes of intermittent infusion and global ischemia. All
protocols were followed by a further 60 minutes of reperfusion,

Figure 1. Experimental perfusion protocols. In all protocols, hearts were perfused with KHB at constant pressure
equivalent to 75 mm Hg both before and after ischemia. Study 1A, Hearts were randomly assigned to one of four
groups (n = 6 per group): oxy-KHB (i), multidose oxygenated (95% oxygen/5% carbon dioxide) KHB infused for 3
minutes at 14 mL/min before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia;
dehy-KHB (ii), multidose deoxygenated (95% nitrogen/5% carbon dioxide) KHB infused for 3 minutes at 14 mL/min
before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia; oxyesmolol (iii),
multidose oxygenated (95% oxygen/5% carbon dioxide) esmolol infused for 3 minutes at 14 mL/min before and every
15 minutes during 60 minutes of intermittent infusion and global ischemia; and deoxyesmolol (iv), multidose
doxygenated (95% nitrogen/5% carbon dioxide) esmolol infused for 3 minutes at 14 mL/min before and every 15
minutes during 60 minutes of intermittent infusion and global ischemia. All protocols were followed by further 60
minutes of reperfusion, when recovery of myocardial function was measured. Study 1B, Hearts were randomly
assigned to one of three ischemic duration groups: 60, 75, 90, and 120 minutes of ischemia. In addition, for each
ischemic duration group, hearts were randomly assigned to four treatment groups (n = 6 per group): multidose
KHB infused at constant flow (CF) for 3 minutes at 14 mL/min before and every 15 minutes during intermittent
infusion and global ischemia, multidose KHB infused at constant pressure (CP) for 3 minutes at 45 mm
Hg before and every 15 minutes during intermittent infusion and global ischemia, multidose esmolol cardioplegia
infused at constant flow for 3 minutes at 14 mL/min before and every 15 minutes during intermittent infusion and
global ischemia, and multidose esmolol cardioplegia infused at constant pressure for 3 minutes at 45 mm Hg before
and every 15 minutes during intermittent infusion and global ischemia. All protocols were followed by further 60
minutes of reperfusion, when recovery of myocardial function was measured.
when recovery of myocardial function was measured (Figure 1, study 1A).

**Study 1B: Comparison of myocardial protection by multidose St Thomas’ Hospital cardioplegic solution No. 2 and esmolol cardioplegia.** Hearts were randomly assigned to one of three groups (n = 6 per group): (v) STH2, multidose normoxic (equilibrated with room air) STH2 infused for 3 minutes at 45 mm Hg before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia; (vi) oxy-STH2, multidose oxygenated (95% oxygen/5% carbon dioxide) STH2 infused for 3 minutes at 45 mm Hg before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia; and (vii) oxesmolol, multidose oxygenated (95% oxygen/5% carbon dioxide) esmolol infused for 3 minutes at 45 mm Hg before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia. All protocols were followed by a further 60 minutes of reperfusion, when recovery of myocardial function was measured (Figure 1, study 1B).

**Study 2: Cardioprotective efficacy of multidose esmolol cardioplegia during prolonged ischemic durations.** Hearts were randomly assigned to one of four ischemic duration groups: 60, 75, 90, and 120 minutes of ischemia. In addition, within each ischemic duration group, hearts were randomly assigned to four treatment groups (n = 6 per group): constant-flow KHB, multidose KHB infused for 3 minutes at 14 mL/min before and every 15 minutes during intermittent infusion and global ischemia; constant-pressure KHB, multidose KHB infused for 3 minutes at 45 mm Hg before and every 15 minutes during intermittent infusion and global ischemia; constant-flow esmolol, multidose esmolol cardioplegia infused for 3 minutes at 14 mL/min before and every 15 minutes during intermittent infusion and global ischemia; and constant-pressure esmolol, multidose esmolol cardioplegia infused for 3 minutes at 45 mm Hg before and every 15 minutes during intermittent infusion and global ischemia. All protocols were followed by a further 60 minutes of reperfusion, when recovery of myocardial function was measured (Figure 1, study 2).

**Expression of Results**

Postischemic recoveries of LVDP, heart rate, and coronary flow were expressed as percentage of baseline values at the end of 20 minutes of aerobic perfusion; LVEDP was expressed as an absolute value (in millimeters of mercury). In addition, changes in infusion pressure or infusion volume during drug infusion were expressed as absolute values (in millimeters of mercury or milliliters per minute).

**Statistical Analysis**

Statistical analysis was performed with StatView and SuperANOVA (SAS Institute, Inc, Cary, NC) on an Apple Macintosh computer (Apple Computer, Inc, Cupertino, Calif). All data are reported as mean ± SEM. Comparisons between groups were assessed for significance by 1-way analysis of variance with post hoc analysis with the Fisher protected least significant difference test, which allowed multiple comparisons (or the Scheffé test when appropriate). The Student paired t test was used to compare paired means.

**Results**

**Study 1A: Effects on Myocardial Protection of Oxygenation During Multidose Infusion of Esmolol Cardioplegia**

The mean baseline values for LVDP, coronary flow, heart rate, and LVEDP after 20 minutes of aerobic perfusion are shown in Table 1. There were no significant differences between groups in any of these values.

**Recovery of function**

**Left ventricular developed pressure, coronary flow, and heart rate.** The changes in recovery of LVDP during 60 minutes of reperfusion after 60 minutes of intermittent global ischemia are shown in Figure 2, A. Hearts subjected to multidose infusions of deoxy-KHB had almost no recovery, whereas those subjected to oxy-KHB recovered rapidly to a plateau value around 60% by 20 minutes. Addition of 1 mmol/L esmolol to either oxy-KHB or deoxy-KHB provided significant additional protection, improving recovery by approximately 40% in either case (Figure 2, A, Table 1), although the rate at which this was achieved was much slower (reaching a plateau by 30 minutes) in the deoxygenated group (Figure 2, A). Interestingly, oxygenation improved recovery by approximately 50% in each case, indicating the highly significant impact of oxygenation of these solutions.

Recovery of coronary flow (after 60 minutes of intermittent global ischemia) throughout 60 minutes of reperfusion is shown in Figure 3, A. Similar values were observed in both deoxygenated groups, reaching 60% by 5 minutes and only increasing slowly to 70% to 80% by 60 minutes. In contrast, both oxygenated groups exhibited a hyperemic response (around 110% recovery) at 5 minutes, and this was sustained in the oxyesmolol group but decreased in the oxy-KHB group to similar levels as the deoxygenated groups (Figure 3, A). Recovery of heart rate (Table 1) was similar in all groups and hence did not appear to be related to oxygenation.

**Left ventricular end-diastolic pressure.** Essentially, LVEDP recovery mirrored the results seen for LVDP; thus, high values of LVEDP were maintained in the deoxygenated groups, with lower values in the oxygenated groups. The addition of esmolol to each solution was associated with a beneficial decrease in LVEDP.

**Infusion pressure of constant-flow infusions during ischemia.** Infusion pressures at each of the four infusions (before and every 15 minutes throughout ischemia) remained relatively constant for the oxygenated solutions but increased significantly with each infusion of the deoxygenated solutions (Figure 4, A).

**Study 1B: Comparison of Myocardial Protection by Multidose STH2 and Esmolol Cardioplegia**

The mean baseline values for LVDP, coronary flow, heart rate, and LVEDP after 20 minutes of aerobic perfusion are
TABLE 1. Baseline values (measured after equilibration of 20 minutes aerobic perfusion) and percentage recovery (after 60 minutes of intermittent global ischemia and 60 minutes of reperfusion) of LVDP, coronary flow, heart rate, and LVEDP

<table>
<thead>
<tr>
<th></th>
<th>Oxy-KHB</th>
<th>Deoxy-KHB</th>
<th>Oxymesmolol</th>
<th>Deoxyesmolol</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVDP (mm Hg)</td>
<td>125 ± 14</td>
<td>119 ± 12</td>
<td>129 ± 8</td>
<td>111 ± 6</td>
</tr>
<tr>
<td>Recovery (%)</td>
<td>58.3 ± 9.0*</td>
<td>4.4 ± 1.5</td>
<td>97.2 ± 4.7†</td>
<td>44.7 ± 7.6*</td>
</tr>
<tr>
<td>Coronary flow (mL/min)</td>
<td>13.2 ± 0.6</td>
<td>11.2 ± 0.8</td>
<td>12.2 ± 0.7</td>
<td>11.4 ± 0.3</td>
</tr>
<tr>
<td>Recovery (%)</td>
<td>61.3 ± 2.3</td>
<td>77.8 ± 10.8</td>
<td>107.5 ± 13.9†</td>
<td>66.6 ± 5.1</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>273 ± 7</td>
<td>269 ± 12</td>
<td>245 ± 7</td>
<td>285 ± 8</td>
</tr>
<tr>
<td>Recovery (%)</td>
<td>95.6 ± 2.9</td>
<td>104.9 ± 5.6</td>
<td>107.4 ± 7.2</td>
<td>88.5 ± 3.9</td>
</tr>
<tr>
<td>LVEDP (mm Hg)</td>
<td>5.8 ± 1.6</td>
<td>7.0 ± 1.0</td>
<td>5.7 ± 1.3</td>
<td>6.7 ± 0.6</td>
</tr>
<tr>
<td>Final LVEDP (mm Hg)</td>
<td>29.8 ± 8.4</td>
<td>72.3 ± 4.1†</td>
<td>8.8 ± 3.3†</td>
<td>42.7 ± 4.4</td>
</tr>
</tbody>
</table>

The differences between groups in baseline values could be due to chance (P > .2).

*P < .05 versus deoxy-KHB.
†P < .01 versus other groups.
‡P < .05 versus deoxy-KHB.

shown in Table 2. There were no significant differences between groups in any of these values.

Recovery of function

Left ventricular developed pressure, coronary flow, and heart rate. The recovery profiles of LVDP after 60 minutes of intermittent global ischemia (expressed as a percentage of preischemic baseline value) are shown for each group in Figure 2, B. Hearts from all groups recovered rapidly and reached a plateau level within 5 to 20 minutes of reperfusion. As before, hearts infused with multidose esmolol cardioplegia recovered extremely rapidly to preischemic values, which were significantly higher than the STH2 groups. Interestingly, there were no differences in recovery between hearts subjected to oxy-STH2 and normoxic STH2. Recovery of coronary flow during 60 minutes of reperfusion after 60 minutes of intermittent global ischemia (Figure 3, B) was similar to that in the previously described study (study 1A). Thus recovery of coronary flow in hearts subjected to multidose oxygenated esmolol was maintained at values that were significantly higher (approximately 120%) than preischemic baseline values (P < .05 vs preischemic value). In contrast, hearts from both STH2 groups had similar patterns of recovery, with coronary flow reaching a hyperemic peak at 5 minutes of reperfusion followed by a subsequent decline throughout the remaining reperfusion period.

Recovery of heart rate (Table 2) was similar in all groups, with no significant differences among all groups.

Left ventricular end-diastolic pressure. Recovery of LVEDP in all groups was similar to the corresponding preischemic value. There were no differences between groups throughout the reperfusion period.

Infusion volume of constant pressure-infusions during ischemia. Infusion volume at each infusion (before and every 15 minutes throughout ischemia) remained relatively constant for both STH2 groups (Figure 4, B), although oxy-STH2 group volumes were significantly higher than those of STH2 and oxymesmolol groups. Interestingly, the volume in the oxymesmolol group decreased significantly at the second infusion but remained constant thereafter.

Study 2: Cardioprotective Efficacy of Multidose Esmolol Cardioplegia During Prolonged Ischemic Durations

We have shown that multiple infusions of oxygenated esmolol cardioplegia completely protected hearts subjected to 45 minutes20 and 60 minutes (this study) of 37°C global ischemia, regardless of the method of infusion (constant flow or constant perfusion pressure). This study was therefore conducted to investigate the protective efficacy of multidose esmolol cardioplegic infusions during prolonged ischemia and also to determine whether the method of infusion influences this protection.

The mean baseline values of LVDP ranged from 105.2 ± 4.8 to 129.0 ± 8.4 mm Hg in all groups; there were no significant differences between groups. Similarly, coronary flow ranged from 9.3 ± 0.3 to 12.0 ± 1.5 mL/min and heart rate ranged from 253.7 ± 12.0 to 283.5 ± 7.2 beats/min, with no significant differences between groups.

Recovery of function

Left ventricular developed pressure, coronary flow, and heart rate. Postischemic recovery of LVDP with increasing duration of global ischemia is shown in Figure 5, A. Hearts subjected to multidose esmolol cardioplegia infused at constant pressure had complete recovery (approximately 100% of preischemic values) for as long as 90 minutes of 37°C global ischemia and only decreased to 60.5% ± 4.9% after 120 minutes of 37°C global ischemia. In hearts in which esmolol cardioplegia was infused at constant flow, however, although recovery was 98.4% ± 5.2% after 60 minutes of 37°C global ischemia (confirming the results obtained in study 1A), recovery had decreased dramatically to only 40.7% ± 4.3% by 75 minutes of 37°C global ischemia. Surprisingly, further increases in ischemic
duration (90 and 120 minutes) did not result in further
decreases (with recoveries of 39.2% ± 5.6% and 29.1% ± 6.6%, respectively).

Recovery of hearts subjected to multidose KHB infusion,
either constant flow or constant pressure, decreased in a
linear fashion with increasing duration of ischemia. Myo-
cardial protection was significantly less than that with con-
stant-pressure esmolol cardioplegia but was similar to that
of constant-flow esmolol cardioplegia at all ischemic dura-
tions except 60 minutes.

Recovery of coronary flow in the esmolol cardioplegia–
treated hearts was similar to that of LVDP. Hearts treated
with KHB had a relatively constant recovery of coronary
flow of around 80% after all ischemic durations.

Surprisingly, the postischemic recovery of heart rate was
similar in all groups but tended to be slightly higher in the
KHB-treated hearts than in the esmolol cardioplegia–treated
hearts.

**Left Ventricular End-Diastolic Pressure.** Changes in
postischemic LVEDP (after 60 minutes of reperfusion) with
increasing ischemic durations are shown in Figure 5, B. In
each group, postischemic LVEDP increased with increasing duration of ischemia. In hearts with constant-pressure esmolol cardioplegia, LVEDP was significantly lower than in other groups at 75 and 90 minutes of ischemia but had increased to similar values by 120 minutes of ischemia. In contrast, LVEDP increased dramatically between 60 and 75 minutes of ischemia in hearts with constant-flow esmolol cardioplegia but then remained relatively constant.

**Infusion Volume of Constant-Pressure Infusion During Ischemia.** The infusion volumes at each infusion during ischemia of either KHB or esmolol during constant-pressure infusion are shown in Figure 6, A. Infusion volume decreased with each infusion in the hearts treated with esmolol cardioplegia, whereas infusion volume changes in the KHB-treated hearts were minimal.

**Infusion Pressure of Constant-Flow Infusions During Ischemia.** The infusion pressures at each infusion during ischemia of either KHB or esmolol during constant-flow infusion are shown in Figure 6, B. KHB-treated hearts had minimal changes in infusion pressure for each infusion; in contrast, infusion pressure in the hearts treated with esmolol cardioplegia increased at each infusion. This was particularly evident between the fourth (60 minutes) and fifth (75 minutes) infusions, associated with a significant change in postischemic recovery of LVDP (Figure 5, A).

**Discussion**

This study demonstrated that although oxygenation of an esmolol-based arresting solution (esmolol cardioplegia) was essential for complete myocardial protection, esmolol itself exerted a significant protective effect. In contrast, multidose esmolol cardioplegia was also shown to provide myocardial protection superior to that of STH2 under the same conditions. Furthermore, recovery of hearts protected with multidose oxygenated esmolol cardioplegia infused at a constant pressure during 37°C global ischemia remained at approximately 100% of preischemic values for as long as 90 minutes.

**Multidose, Oxygenated Infusions and Myocardial Protection**

Multidose infusion of hyperkalemic cardioplegia during global ischemia improves myocardial protection relative to
single-dose cardioplegia. Previously, we demonstrated that multidose infusions of oxygenated esmolol cardioplegia provided myocardial protection superior to that of a single infusion; therefore, in this study, all cardioplegic solutions were administered as multidose infusions. For normothermic ischemia, the initial cardioplegic infusion acts to arrest contraction (conserving energy); cellular metabolic activity will continue, however, and various anaerobic metabolites such as lactate and protons will accumulate in the tissue. Subsequent cardioplegic infusions remove toxic metabolites, provide a small amount of oxygen for residual oxidative metabolism, and (with some solutions) provide substrates for anaerobic metabolism. In this study, the short half-life (9 minutes) of esmolol means that its pharmacologic effect will rapidly diminish, allowing the return of contractile activity; periodic replenishment of this solution would, therefore, be important to maintain diastolic arrest. A potential disadvantage of multidose cardioplegia under normothermic conditions might be the additional exposure of the myocardium to calcium, sodium, and water, thereby promoting tissue edema.

Clinically, intermittent ischemia (with or without fibrillation) and reperfusion continues to be used by some surgeons (particularly in the United Kingdom) with good results, and we previously demonstrated that intermittent global ischemia has an intrinsic myocardial protective effect equivalent to that of a crystalloid cardioplegia (STH2). That finding was confirmed by this study. Thus the beneficial effect observed with multidose esmolol is likely to be biphasic, involving both the protective effect of esmolol and that of intermittent reperfusion, and this supposition was confirmed by the results from the deoxy-KHB and deoxyesmolol groups in study 1A. Vascular washout (by intermittent reperfusion) removes harmful metabolic products (such as lactate, protons, or inorganic phosphate) from the myocardium, reducing the cumulative effects of these products during subsequent ischemia. In this study, however, hearts treated with multidose infusion of deoxy-KHB (intermittent washout of metabolites only) had a poor recovery, suggesting that intermittent oxygenation rather than intermittent washout was of primary benefit. Furthermore, esmolol added to deoxy-KHB enhanced myocardial recovery to a value that was similar to that seen with oxy-KHB, confirming the independent protective effect of esmolol.

Most studies investigating the protective effect of oxygenation of crystalloid hyperkalemic cardioplegic solutions have demonstrated beneficial effects on the myocardium, both experimentally and clinically; others, however, have been unable to demonstrate these beneficial effects. In this study (1B) we also failed to demonstrate an improvement in recovery of function with oxygenated STH2 relative to normoxic STH2; however, a number of differences between this and previous investigations may account for these effects. In this study STH2 was gassed with 95% oxygen/5% carbon dioxide (which maintained the pH at pH 7.0), as was esmolol cardioplegia (which had a pH of 7.4 with this gas mixture). In contrast, previous studies used 100% oxygen in STH2, which caused a significant alkalosis and a depressed recovery of function. Although STH2 is usually adjusted to pH 7.8 before use, experimental
studies have demonstrated that an alkaline pH may not be optimal and that it should be used at neutral or slightly acidic pH values for optimal efficacy. In addition, when 100% oxygen was used, ST2 and the ensuing ischemia were hypothermic (10°C-20°C); this ought to favor a more alkaline pH, but it has been shown that ST2 only changes by 0.05 of a pH unit across the range of 10°C to 40°C. Thus the pH values of the cardioplegic solutions used in this study were closer to the optimum value, and this may account for some of the differences between these studies and others. It is also possible that increased myocardial oxygen consumption at normothermia relative to delayed consumption at hypothermia (with the improved maintenance of high-energy phosphate compounds) may have influenced these differing results.

In contrast, it is obvious that oxygenation of esmolol cardioplegia plays an important role in its myocardial protection. Multidose infusion (every 15 minutes) of oxygenated esmolol (oxy-KHB containing 1 mmol/L esmolol) completely protected hearts during 60 minutes of 37°C global ischemia, whereas deoxygenated esmolol (gassed with 95% nitrogen/5% carbon dioxide) was significantly less protective. However, deoxy-KHB gave almost no protection, indicating a significant protective effect for esmolol per se. It is possible that esmolol, by reducing myocardial oxygen demand, delays injury to the ischemic myocardium, and that reperfusion (reinfusion) with oxygenated esmolol cardioplegia at a time when the protected myocardium is still reversibly damaged may attenuate ischemic injury. If, on the other hand, reperfusion is initiated too late or anoxia continues, the myocardium is irreversibly injured, and esmolol fails to protect fully. Interestingly, Toleikis and Tomlinson also demonstrated that acute β-blockade, both before and during a relatively short (30-minute) period of normothermic low-flow global ischemia in isolated rabbit hearts, was protective, whereas similar treatment through 60 minutes of ischemia was ineffective, supporting our suggestion that β-blockers are only likely to be protective during short periods of ischemia. Thus intermittent aerobic reperfusion may be required for esmolol cardioplegia to provide full myocardial protection.

Method of Infusion: Constant Flow Versus Constant Pressure

The direct vascular effects of esmolol were examined by Gorczynski in constant-flow–perfused hind limbs of pentobarbital-anesthetized, ganglion-blocked dogs. That study indicated that esmolol is devoid of direct vascular effects at doses that are within or above the β-blocking range but that extremely large doses may cause vasoconstriction. Murthy and Frishman showed that intravenous infusion of esmolol increased both mean coronary resistance and diastolic coronary resistance in dogs under barbiturate anesthesia. Our study confirmed these findings when esmolol cardioplegia was infused at constant flow and perfusion pressure was monitored (Figure 6, B). Infusion pressure increased significantly at the fifth infusion and was closely correlated with a significant decrease in recovery of LVDP (Figure 5, A) and increased LVEDP (Figure 5, B); hence, this increased infusion pressure (coronary vascular resistance) appeared to be a cause of myocardial injury. Similarly, increasing numbers of infusions of esmolol cardioplegia at constant pressure resulted in a decline in infusion volume (reflecting the vasoconstrictive action of esmolol and associated with a considerably larger increase in coronary vascular resistance [data not shown] in both study 2 and study 1A), but that was not associated with a depressed recovery of function.

The lower coronary vascular resistance observed in constant-flow–infused hearts may be an artificial consequence of the infusion being forced through the vasculature (caus-
ing vascular injury) and may lead to increased tissue edema, which would lead to deterioration in postischemic function. Although myocardial edema was not measured in this study, constant-pressure esmolol perfusion has previously been shown to minimize myocardial edema. We observed significantly lower LVEDP levels in hearts infused with esmolol cardioplegia at constant pressure (Figure 5, B), which would tend to support this suggestion.

**Possible Protective Mechanisms of Esmolol**

In this study, hearts infused (3 minutes every 15 minutes at constant pressure of 45 mm Hg) with oxygenated esmolol cardioplegia were completely protected for as long as 90 minutes of 37℃ global ischemia. It is intriguing to speculate on how this could be achieved.

Initiation of ischemic arrest is associated with an accelerated release of endogenous catecholamines, producing a period of hypermetabolic function. This results in depletion of intracellular high-energy phosphate stores, which sharply reduces the tolerance of the cell to ischemia. The best available technique to maintain this tolerance involves reducing cell metabolism, thereby avoiding the period of hypermetabolic function and reducing the oxygen demands of the cell. We have previously shown that esmolol cardioplegia induces a rapid arrest (at a mean duration of around 50 seconds), which is similar to that of St Thomas’ Hospital cardioplegia (around 35 seconds) and significantly shorter than ischemia alone (around 220 seconds). It is likely that part of the protective mechanism of esmolol cardioplegia involves maintenance of high-energy phosphates by rapid reduction of energy demands. β-Blockers, administered either before or just after ischemia, have been shown in numerous animal models to exert beneficial effects on ischemic myocardium. Although the mechanism for these benefits are unknown, speculations include improved balance between oxygen supply and demand by reducing oxygen demand through negative inotropic and chronotropic actions, increased oxygen supply as a result of increased blood flow to ischemic areas, and redistribution of blood flow from the subepicardium to the subendocardium. We also observed that hearts treated with oxygenated esmolol had a significantly higher coronary flow, which was sustained throughout the reperfusion period. This elevated coronary flow would considerably increase the available oxygen supply to the previously ischemic myocardium and thus represents a potential additional mechanism by which esmolol exerted its protective effect in this study. Thus multidose infusions of oxygenated esmolol cardioplegia may combine the protection that we previously observed with intermittent global ischemia and reperfusion with that of rapid cardiac arrest (which decreases myocardial oxygen consumption), thereby enhancing overall protection.

**Limitations of This Study**

We concede that these studies were conducted in rat hearts perfused with a crystalloid solution rather than blood and that this is a relatively unphysiologic situation. We are aware that esmolol is metabolized by blood esterases; consequently, this study would fail to reveal any interaction between the metabolism of esmolol and the cardioprotective efficacy of esmolol. It would be important to establish whether blood-based esmolol cardioplegia would be as effective as the crystalloid solutions used in these studies, and further studies are warranted.

It is also possible that esmolol may have adverse systemic effects that would not be revealed in our study; this would require investigation in the intact animal. Previous studies have used esmolol clinically during relatively long-term continuous infusions (albeit at lower concentrations), with no reports of any systemic adverse effects. Hence, we speculate that multiple, short, high-dose infusions are unlikely to have major systemic effects, although this would need verification.

Myocardial ischemic disease is a multifactorial process; there is a spectrum of injury that affects the method of myocardial protection. Hearts used in this study were taken from healthy rats, and it is likely that any protective effect of esmolol would be different in jeopardized hearts suffering from ischemic injury or disease. In addition, any such hearts are likely to require prolonged periods of ischemia to correct the lesion, and we have shown that multidose esmolol infusions are effective for relatively prolonged ischemic durations at 37℃.

Although it is dangerous to extrapolate from experimental studies in the isolated rat heart to the clinical situation, there are a number of potential clinical benefits that might be available with the use of esmolol cardioplegia. The total volume of esmolol required to induce and maintain cardiac arrest is quite low (the addition of a suitable volume of esmolol to oxygenated blood to make up a 1 mmol/L concentration) relative to potassium cardioplegia, for which volumes in excess of 1000 mL are required. Consequently, additional hemodilution during cardiopulmonary bypass would be avoided with esmolol arrest, in contrast to warm continuous-infusion of blood cardioplegia or the cardiac surgical condition induced with esmolol added to blood for continuous infusion. Multidose intermittent esmolol infusion would provide a still and blood-free operating field during warm (normothermic) heart surgery. This technique of multidose esmolol infusion can be used for coronary artery bypass surgery, or any other type of cardiac surgery.

**Conclusion**

Oxygenation of the esmolol cardioplegia was essential for optimal myocardial protection, and it was shown to be more efficacious than the well-established STH2. Moreover, multidose infusions of oxygenated esmolol cardioplegia main-
tained complete protection for normothermic ischemic periods as long as 90 minutes. Esmolol cardioplegia thus may provide on efficacious alternative to hypokalemia.

Dr Ryuzo Bessho was a visiting research fellow from the Division of Cardiovascular Surgery, the Department of Surgery II, Nippon Medical School, Tokyo, Japan.

References

Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat
Ryuzo Bessho and David J. Chambers
*J Thorac Cardiovasc Surg* 2002;124:340-351

**Continuing Medical Education Activities**
Subscribers to the Journal can earn continuing medical education credits via the Web at
http://cme.ptsnetjournals.org/cgi/hierarchy/ptsnetcme_node:JTCS

**Subscription Information**
This article cites 32 articles, 17 of which you can access for free at:
http://jcts.ptsnetjournals.org/cgi/content/full/124/2/340#BIBL

**Citations**
This article has been cited by 3 HighWire-hosted articles:
http://jcts.ptsnetjournals.org/cgi/content/full/124/2/340#otherarticles

**Subspecialty Collections**
This article, along with others on similar topics, appears in the following collection(s):
Myocardial protection
http://jcts.ptsnetjournals.org/cgi/collection/myocardial_protection

**Permissions and Licensing**
General information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
An on-line permission request form, which should be fulfilled within 10 working days of receipt, is available at:
http://www.elsevier.com/wps/find/obtainpermissionform.cwsecome/obtainpermissionform